Health Literacy Matters in Rheumatic Disease Care

Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systol

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/pFBKjXqwfr

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to

Social Author Image
https://pbs.twimg.com/profile_images/1823684670921277440/AXfoLXmo_normal.jpg
Tweet Author
AdelaCastro222
Social Author Name
Adela Castro
Tweet Content
Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains. -Clinical efficacy maintained until week 52. -No major safety signals reported. -Notably high placebo response rates. Abstract
11 June 2025
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-IL

Social Author Image
https://pbs.twimg.com/profile_images/1823684670921277440/AXfoLXmo_normal.jpg
Tweet Author
AdelaCastro222
Social Author Name
Adela Castro
Tweet Content
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/KpH05w1S9O
Links
https://x.com/AdelaCastro222/status/1932799331133800941/photo/1
11 June 2025
Combination treatments in Psoriatic Arthritis
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.

LIVE Daily Recap – EULAR 2025 Coverage Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14 Time: 12 (noon) ET ?

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
LIVE Daily Recap – EULAR 2025 Coverage Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14 Time: 12 (noon) ET 🔗 Tune in and join the conversation: YouTube, X, Facebook Live & LinkedIn #RheumNow#EULAR25 #Rheumatology #MedTwitter #HCPs #RheumatologyEducation https://t.co/1qlcKDOL64

Efficacy and Safety of Xeligekimab in AS

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×